Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 63, Issue 9, Pages 4749-4761Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.0c00007
Keywords
-
Categories
Funding
- Bill and Melinda Gates Foundation
- Foundation for the National Institute of Health (NIH) [OPP1024021]
- Foundation for the National Institutes of Health (FNIH) [OPP1158806]
- European Community [260872]
- FCT PhD grant [SFRH/BD/81735/2011]
- Ministry of Education, Science, Research and Sport of the Slovak Republic [VEGA 1/0301/18]
- Slovak Research and Development Agency [DO7RP-0015-11]
- Research and Development Operational Programme - European Regional Development Fund [ITMS 26240120027]
- Fundação para a Ciência e a Tecnologia [SFRH/BD/81735/2011] Funding Source: FCT
Ask authors/readers for more resources
Tuberculosis (TB) remains a leading cause of mortality among infectious diseases worldwide. InhA has been the focus of numerous drug discovery efforts as this is the target of the first line pro-drug isoniazid. However, with resistance to this drug becoming more common, the aim has been to find new clinical candidates that directly inhibit this enzyme and that do not require activation by the catalase peroxidase KatG, thus circumventing the majority of the resistance mechanisms. In this work, the screening and validation of a fragment library are described, and the development of the fragment hits using a fragment growing strategy was employed, which led to the development of InhA inhibitors with affinities of up to 250 nM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available